Nanchang outdoor sample no longer wear protective cloth

Since July, abnormal high temperatures in various places have a greater impact on residents. Especially this week, residents have died in many places due to heat irritation.

The seventh batch came to an end this week. According to Shanghai Sunshine Pharmaceutical Procurement Network, the average price reduction of drugs is 48%of the proposed drugs. According to the original scheduled purchase volume, the cost savings brought by the price reduction reached 18.5 billion yuan;

2022 has passed in the first half of the year, but the development of biomedical companies is still difficult. Baiji PD-1 is blocked in the sea. The well-known biomedical company has been exposed to "acquisition", and the upstream CXO was once suspected of the market ...

More information, sort out as follows:

Heavy policy

1. The fever of the "hot dead" is followed by the Health Commission

Since July, the temperature in many places has approached 40 °, and the red high -temperature warning signal has also become a daily temperature warning in various places. According to many media reports, in the past week, there have been armal radiation cases in Nanjing, Zhejiang, Xi'an and other places, and even multiple deaths have occurred.

On July 15, the National Health and Health Commission Medical and Health Management Bureau specially published articles to clarify the symptoms and causes of thermal radiation disease, and stated that the temperature of the body temperature continued to rise in summer, even exceeding 40 °, headache, muscle under high temperature environment, muscle muscles under the high temperature environment, muscle muscles Symptoms such as spasm, light breathing, and nausea should be treated in time.

According to the latest news, the outdoor nucleic acid sampling personnel of Nanchang City in Jiangxi cancel wear protective clothes, switch to one -time isolation clothes, and change the post for one hour.

Thermal radiation disease is the most serious situation in related emergencies at high temperatures, which can be understood as severe heat stroke. This emergency is due to the imbalance of the body regulating function in a high temperature and high humidity environment. The heat production is greater than the heat dissipation, and the temperature rises rapidly, exceeding 40 °. It is often accompanied by severe fatal diseases of multi -organ dysfunction, and the mortality rate is extremely high.

According to a global temperature data map released by NASA, extreme high temperature phenomena have appeared in many places around the world. According to Spain's release, 84 people in Spain died of high temperatures from July 10th to 12th from July 10th to 12th.

Picture source: NASA Global Temperature Data Map

2. Director of Xi'an Emergency Center is "double -open"

On July 12, Shaanxi Discipline Inspection and Supervision passed the news that the former deputy secretary and director of the Xi'an Emergency Center Li Qiang were expelled from the party and expelled from public office; the obtained from disciplinary violations and violations; The property involved is transferred.

According to Guan Wei, during his reign, Li Qiang had received gifts, gifts, and shopping cards that might affect fair execution of official duties, and accepted a banquet that could affect fair execution of official duties. The bad atmosphere has a serious negative impact and adverse consequences on the prevention and control of the Xi'an outbreak.

It is understood that at the beginning of the year, a pregnant woman broke out that a pregnant woman was unable to go to the consultation due to the timeout of nucleic acid testing, which led to the abortion incident. The Xi'an Discipline Inspection Commission had given Li Qiang a warning to the party.

3. Last year, the new Chinese medicine new medicine was approved to break through the double digits for the first time

This week, at the State Pharmaceutical Bureau and the National Traditional Chinese Medicine Science Supervision Conference, the National Medicine Bureau and the China Health Media Group, the "2021 National Chinese Medicine Regulatory Blue Book" was officially released.

According to the "Blue Book", in 2021, there were 12 new Chinese medicines for listing in my country, which exceeded double digits for the first time. These approved new Chinese medicines have carried out random, double -blind, placebo parallel control group, and multi -center clinical trial research.

Three of the 12 new Chinese medicines from the new Chinese medicines from the ancient classic prescriptions, which are the "three -party" achievements in the new crown epidemic.

Industry affairs

1. Affected by the collection, Gan Li Pharmaceutical's pre -losing loss in the first half of the year

On July 14, Gan Li Pharmaceutical issued a pre -loss announcement: 168 million yuan to 200 million yuan in the first half of the year. This is the first half of Gan Li Pharmaceutical's losses since 2017.

The main revenue of Ganli Pharmaceutical comes from insulin preparations. In the first half of this year, the company's products were included in the sixth batch of collection, and the price reductions were more price reductions, and the implementation of the country was slow. In the short term, sales growth could not hedge the impact of decline in prices, resulting in a significant decline in revenue and net profit.

2. The overall performance ofcxo has pre -increased, and the capital market does not buy a bill

This week, a number of CXO companies announced the performance trailer for the first half of 2022.

Yaoming Kant announced that it was expected to revenue of 17.756 billion yuan, an increase of 68.52%year -on -year; net profit reached 4.636 billion yuan, a year -on -year increase of 73.29%;

Kailaiying announced that it was expected to revenue of 4.79 billion yuan-50.58 billion yuan, an increase of 172.18%-187.37%year-on-year; net profit was 1.644 billion yuan -1.743 billion yuan, a year-on-year increase of 282.99%-305.97%;

Zhaoyan New Pharmaceutical announced that the net profit in the first half of the year increased by 121.8%-161.8%compared with the same period.

Although the performance is good, the market does not pay. During this week, Yin Ming Kangde fell 4.72%, Kailei fell 11.08%, and Zhaoyan's new drugs fell 3.93%. "Insufficient orders for new crown medicines" have become the reason for the hot market.

3. Baiji Shenzhou PD-1 is approved in the United States due to the epidemic

On July 14, Baiji Shenzhou issued an announcement stating that due to the impact of the new crown epidemic, the FDA in the United States could not complete the on -site inspection of the on -site inspection in China, so the FDA extended the Rayleyzer's counterpart. The evaluation incident of the second -tier treatment permit application of the squamous cell carcinoma patients was completed until the on -site verification was completed. In September 2021, the FDA accepted the application for a new drug listing license for Penji PD-1. According to the rules of the United States, the review date of the review of this application should be July 12 this year. The FDA currently only informed Baiji Shenzhou to be unable to verify on the spot and did not give the updated resolution date.

Earlier, the PD-1 of Junshi Bio was postponed because of similar problems.

4. Cornerstone Pharmaceuticals or seek to be acquired

This week, according to a number of media, the cornerstone pharmaceutical industry, which is mainly engaged in anti -cancer drugs, is considering selling equity or finding buyers to comprehensively acquire it, mainly because its domestic and foreign business prospects are unclear.

It is understood that the PD-L1 monoclonal anti-anti-resistance of Cornerstone Pharmaceutical was approved in China in December 2021 to treat metastatic non-small cell lung cancer. Not long ago, the second indication of the drug was just approved by the Drug Administration, which was also treated with non -small cell lung cancer.

There are no less than 10 species of PD-1/PD-L1 currently listed in China. Non-small cell lung cancer categories have once become the main place for such drugs. Cornerstone Pharmaceutical's PD-L1 is really difficult to survive.

Regarding the rumors of looking for buyers, the cornerstone pharmaceuticals have responded that the company will not comment on the content of recent foreign media reports. At present, the company's business is operating normally.

New drug inventory

1. Real biological new crown oral medicine submit a listing application

On July 15th, the real creature announced that Azf had to submit a listing application to the Pharmaceutical Supervision Bureau, and the indication was the new coronary virus.

According to multiple media reports, in the phase III clinical trial, the proportion of improved on the seventh day after receiving Azf's administration was 40.43%, and the placebo group was 10.87%(P <0.001). The medium -level time of the clinical state is extremely significant statistical differences (P value <0.001); the virus clearance time is about 5 days; the safety is good.

2. CDK4/6 inhibitors for the treatment of small cell lung cancer are approved for listing

On July 13, Xianmang Pharmaceutical issued an announcement saying that it collaborated with G1 Therapeutics, Inc. (G1) CDK4/6 inhibitor injection for inhibitors for inhibitors. Patients with a wide range of small cell lung cancer with systemic chemotherapy, preventive administration before receiving platinum -containing drugs combined with pyride schemes to reduce the incidence of bone marrow suppression caused by chemotherapy.

Earlier, there were three CDK4/6 inhibitors in the world approved to be listed, namely Pfizer's Liberci, Novo Risley, and Eli Lili.

Writing | Nicotinamide

Edit ｜ Jiang Yun Jia Ting

Operation | Valley

- END -